OptimizeRx Corp 8-K

What Happened

• OptimizeRx Corporation announced that its Audit Committee approved the dismissal of independent registered public accounting firm UHY LLP on March 24, 2026, and the firm was subsequently dismissed effective March 25, 2026. The company filed an 8-K on March 30, 2026 to disclose the change.
• UHY’s audit reports on OptimizeRx’s consolidated financial statements for the fiscal years ended December 31, 2025 and 2024 were not adverse or qualified. The company reported no disagreements with UHY on accounting, disclosure or auditing scope during 2024, 2025 or through March 25, 2026.

Key Details

• Audit Committee approval: March 24, 2026; dismissal effective March 25, 2026.
• Prior audit reports (fiscal 2025 and 2024) were unmodified (no adverse opinion or disclaimer).
• No “disagreements” or reportable events with UHY, except a previously disclosed material weakness in internal control related to ensuring completeness and accuracy of data received from third‑party service organizations.
• UHY was authorized to respond to inquiries from the successor auditor; a letter from UHY to the SEC dated March 30, 2026 is included as Exhibit 16.1 to the 8‑K.

Why It Matters

• A change in independent auditor is a material corporate governance event investors track because it can affect future audit opinions and investor confidence. OptimizeRx’s prior audits were unmodified, which is reassuring, but the company has disclosed a material weakness in controls over third‑party data that remains relevant.
• Investors should watch for the name of the successor auditor and any communications about remediation of the material weakness or potential impacts on future financial reporting and audit fees.